The Gross Margin of Egetis Therapeutics AB (publ) (EGTX.ST) is 74.84%.
Gross Margin represents the percentage of revenue that exceeds the cost of goods sold. It reflects a company's efficiency in producing and selling its products.
| Date | Value |
|---|---|
| 2024-12-31 | 74.84% |
| 2023-12-31 | 80.90% |
| 2022-12-31 | 72.12% |
| 2021-12-31 | 79.46% |
| 2020-12-31 | 95.34% |